calcium gluconate süstelahus
laboratorio sanderson s.a - kaltsiumglükonaat - süstelahus - 100mg 1ml 10ml 100tk
calcio gluconate salf infusioonilahus
s.a.l.f. laboratorio farmacologico s.p.a. - kaltsiumglükonaat - infusioonilahus - 100mg 1ml 10ml 5tk
calcium gluconate tablett
jsc kievmedpreparat"" - kaltsiumglükonaat - tablett - 500mg 10tk
calcium gluconate tablett
oao monfarm - kaltsiumglükonaat - tablett - 500mg 10tk
gonazon
intervet international bv - asagly-nafareliin - hüpofüüsi ja hüpotaalamuse hormoonid ja analoogid - dogs; salmonidae (salmonid fish) - naine salmonid kalade, nagu lõhe (salmo salar), vikerforell (oncorhynchus mykiss), jõeforelli (salmo trutta) ja arktika charr (salvelinus alpinus)esilekutsumine ja sünkroonimine ovulatsiooni tootmiseks eyed-muna ja praadida. koerad (emased)ennetamine gonadal funktsiooni emased kaudu pikaajalise blokaadi gonadotropiini süntees.
hemangiol
pierre fabre medicament - propranoloolvesinikkloriid - hemangioom - beetablokaatorid - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.
xeljanz
pfizer europe ma eeig - tofacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 ja 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.
dentocaine 40mg/0,005 mg/ml süstelahus
inibsa dental s.l. - artikaiin+epinefriin (adrenaliin) - süstelahus - 40mg+0,005mg 1ml 1.8ml 50tk
alcaine silmatilgad, lahus
alcon farmaceutika d.o.o. - proksümetakaiin - silmatilgad, lahus - 5mg 1ml 15ml 1tk
septanest süstelahus kolbampullis
septodont - artikaiin+epinefriin (adrenaliin) - süstelahus kolbampullis - 40mg+0,005mg 1ml 1.7ml 200tk; 40mg+0,005mg 1ml 1.7ml 50tk